Drug Trial Radar · NCT05392192
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Apr 7, 2022
Primary completion
Apr 13, 2023
Study completion Apr 13, 2023
Sponsor
- Lead sponsor
- Aldeyra Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough
Conditions
- Chronic Cough
Interventions
ADX-629Drug
Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
PlaceboDrug
Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Serious Adverse EventsTime frame: The safety assessment period was Day 1 - Day 14 for each treatment period.
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Allergy Associates Medical Group, Inc.
San Diego, California
Allergy & Asthma Associates of Santa Clara Valley Research Center
San Jose, California
Cano Research - Hollywood
Hollywood, Florida
Advanced Pulmonary Research Institute
Loxahatchee Groves, Florida
Florida Pulmonary Research Institute LLC
Winter Park, Florida
ClinCept
Columbus, Georgia
Mayo Clinic Pulmonary Clinic Research Unit
Rochester, Minnesota
Mount Sinai
New York, New York
Charlotte Lung & Health/American Health Research
Charlotte, North Carolina
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio
Vital Prospects Clinical Research
Tulsa, Oklahoma
Northwest Research Center
Portland, Oregon
Clinical Research of Rock Hill
Rock Hill, South Carolina
Pharmaceutical Research and Consulting Inc.
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.